Results 1 to 10 of about 5,250 (122)

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

Cancer Medicine, 2022
Background Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and paclitaxel. Methods
Marina N Sharifi, Ruth O'Regan, Jens Eickhoff   +2 more
exaly   +2 more sources

Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor [PDF]

Discover Oncology
Background Synovial sarcoma (SS) is a rare soft tissue sarcoma (STS) with limited treatment options, indicating the need for novel therapeutic strategies.
Noritaka Honda, Hirokazu Taniguchi, Sawana Ono, Fumiko Hayashi, Erika Imamura, Hiroshi Gyotoku, Shinnosuke Takemoto, Takahiro Takazono, Hiroshi Ishimoto, Noriho Sakamoto, Yasushi Obase, Mitsuko Masutani, Tomoya Nishino, Hiroshi Mukae   +13 more
doaj   +2 more sources

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents

Biomedicines, 2021
Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process and the target of several FDA-approved inhibitors. Several of these inhibitors have been radiolabeled for non-invasive imaging of PARP-1 expression or targeted ...
Dong Zhou, Cedric Mpoy, Sadia Afrin
exaly   +3 more sources

Radiosensitization Effect of PARP Inhibitor Talazoparib Involves Decreasing Mitochondrial Membrane Potential and Induction of Cellular Senescence [PDF]

Current Issues in Molecular Biology
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) with radiation therapy can enhance the sensitivity of cancer cells by inhibiting DNA repair pathways.
Barkha Saraswat, Ankitha Vadi Velu, Zhongming Gao, Zongxiang Zhang, Haoyang Zhu, Ying Tong, Mitsuko Masutani   +6 more
doaj   +2 more sources

Expert Consensus on the Clinical Application of Poly ADP Ribose Polymerase Inhibitors in Breast Cancer (2025 Edition). [PDF]

Cancer Innov
This consensus, based on the latest evidence‐based medical data, provides guidance on the standardized application and safety management of PARP inhibitors in breast cancer treatment, aiming to serve as a reference for clinical practice. ABSTRACT Breast cancer represents a major threat to women's health in China.
Ma F, Xu B, China Anti‐Cancer Association Committee on Clinical Research of Anticancer Drugs, National Expert Committee on Monitoring Clinical Application of Antineoplastic Drugs, Breast Cancer Expert Committee of National Cancer Quality Control Center, Expert Committee on Chemotherapy Quality Control of Beijing Cancer Treatment Quality Control and Improvement Center.   +5 more
europepmc   +2 more sources

Case Report: Deep and durable response to talazoparib in germline BRCA2-mutated rectal neuroendocrine carcinoma [PDF]

Frontiers in Oncology
High-grade neuroendocrine carcinoma (NEC) of the rectum is a rare and aggressive malignancy, with limited treatment options and a poor prognosis. We report the successful off-label use of the PARP inhibitor talazoparib in a patient with metastatic ...
Milan Khealani, Byoung Uk Park, Robben Schat, Emmanuel S. Antonarakis, Arjun Gupta   +4 more
doaj   +2 more sources

HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis [PDF]

Therapeutic Advances in Medical Oncology
Background: Talazoparib plus enzalutamide showed significant improvement of progression-free survival in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in homologous recombination repair (HRR) genes.
Mingjun Rui, Yingcheng Wang, Qiran Wei, Joyce H. S. You   +3 more
doaj   +2 more sources

Dual PARP/Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN-Deficient Endometrial Cancer. [PDF]

J Cell Mol Med
ABSTRACT Endometrial cancer (EC) incidence continues to rise, underscoring the need for effective therapies beyond BRCA‐mutant disease. Although PTEN loss, a frequent alteration in EC, has been implicated in impaired homologous recombination and increased sensitivity to PARP inhibitors, responses to PARP inhibitor monotherapy remain variable and are ...
Kang SW, Eum H, Lee JY, Lee MS, Kim YM, Kim TW, Lee SW.   +6 more
europepmc   +2 more sources

The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models [PDF]

Nature Communications
Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit. RT3D interacts
Joan Kyula-Currie, Victoria Roulstone, James Wright, Francesca Butera, Arnaud Legrand, Richard Elliott, Martin McLaughlin, Galabina Bozhanova, Dragomir Krastev, Stephen Pettitt, Tencho Tenev, Magnus Dillon, Shane Foo, Emmanuel C. Patin, Victoria Jennings, Charleen Chan Wah Hak, Elizabeth Appleton, Amarin Wongariyapak, Malin Pedersen, Antonio Rullan, Jyoti Choudhary, Chris Bakal, Pascal Meier, Christopher J. Lord, Alan Melcher, Kevin J. Harrington   +25 more
doaj   +2 more sources

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [PDF]

FEBS Open Bio
We analyzed alterations of PAR metabolism‐related proteins in PARG inhibitor‐resistant HCT116RPDD cells. Although PARG levels remained unchanged, HCT116RPDD cells exhibited reduced PARP1 and ARH3 expression and elevated PAR levels. Interestingly, HCT116RPDD cells exhibited slightly elevated intracellular NAD+/NADH and ATP levels. Our findings suggest a
Tsuda K, Ogino Y, Sato A.
europepmc   +2 more sources